Liptruzet

Active Ingredient(s): Atorvastatin Calcium + Ezetimibe
FDA Approved: * May 3, 2013
Pharm Company: * MERCK SHARP DOHME
Category: Cholesterol

Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet.[1] It has also been approved to reduce elevated total cholesterol and elevated LDL in patients diagnosed with homozygous familial hypercholesterolemia as ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Liptruzet (Atorvastatin 10 mg (As Atorvastatin Calcium 10.34 mg) / Ezetimibe 10 mg) Oral Tablet

NDC: 66582-320

Labeler:

Merck Sharp & Dohme Corp.

Liptruzet (Atorvastatin 20 mg (As Atorvastatin Calcium 20.68 mg) / Ezetimibe 10 mg) Oral Tablet

NDC: 66582-321

Labeler:

Merck Sharp & Dohme Corp.

Liptruzet (Atorvastatin 40 mg (As Atorvastatin Calcium 41.37 mg) / Ezetimibe 10 mg) Oral Tablet

NDC: 66582-322

Labeler:

Merck Sharp & Dohme Corp.

Liptruzet (Atorvastatin 80 mg (As Atorvastatin Calcium 82.73 mg) / Ezetimibe 10 mg) Oral Tablet

NDC: 66582-323

Labeler:

Merck Sharp & Dohme Corp.